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Abstract
Rapid growth of the overweight population and the number of obese individuals in recent decades suggests that
current strategies based on diet, exercise, and pharmacological knowledge are not sufficient to address this
epidemic. Obesity is the result of a high caloric intake and energy storage, not counterbalanced by an equally
important energy expense. Botulinum toxin type A (BoNT-A) use is rapidly expanding to include treatment of a
variety of ophthalmological, gastrointestinal, urological, orthopedic, dermatological, secretory, painful, and
cosmetic disorders. Many studies evaluating the effect of BoNT-A in gastric antrum e/o fundus for the treatment
of obesity have been published. This treatment modality was based on the observation that gastric injection of
BoNT-A in laparatomized rats induced a significant reduction of food intake and body weight. These studies have
been published yielding debated results. Differences in the selection of patients, the doses of BoNT-A, the
method of administration of the toxin, and the instruments of evaluation of some parameters among these studies
may be the cause. In this review, it will study the state-of-the-art use of BoNT-A in obesity basic science models
and review the clinical evidence on the therapeutic applications of BoNT-A for obesity.
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1. Introduction
Obesity is fast emerging as one of the greatest challenges of human health. The number of obese people has
nearly doubled since 1980. According to the World Health Organization (WHO) there are currently about 1.5
billion overweight adults in the world and, of these, 500 million are obese. In addition, about 42 million children
under five years old are overweight or obese.
The situation in the US is quite alarming, with 65% of US adults overweight or obese. Obesity is a risk factor for
a large number of diseases: cardiovascular, metabolic such as type 2 diabetes, and many forms of cancer [1].
At the biological level, obesity results from an imbalance of energy balance in the body. If the input of energy
(introduced with food) consistently exceeds energy expense, the extra energy is transported and stored in the
form of triglycerides [2]. A large number of factors, namely genetic, environmental, behavioral, biological, and
lifestyle factors, play an important role in increasing food consumption and developing overeating disorders [3].
Obesity is defined by body mass index (BMI), which is obtained by dividing a person’s weight by the square of
the person’s height. The BMI does not consider the distribution of body fat, and, because of the relationship
between abdominal obesity with cardiovascular disease (CVD) and other metabolic risk factors in clinical
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practice, it is useful to measure, in addition to BMI, the waist-hip ratio (WHR). The WHR is the ratio of the
circumference of the waist to that of the hips and is calculated as the waist measurement divided by the hip
measurement (W/H) [4,5].
Unfortunately, the traditional therapies based on diet, exercise, behavior modification, and medication have had
little effect, especially in severely obese people. Surgical approaches provide nowadays the most effective
treatment of obesity but present possible risks. Only 1% of patients are estimated to benefit from bariatrics [6].
The burgeoning field of endoluminal therapy allows us today to consider even less invasive 0procedures to reach
a broader population of obese patients.
Botulinum neurotoxins, produced by the bacterium Clostridium botulinum, have been widely applied medically
since the first use of BoNT-As for ocular strabismus [7]. In 1993, Pasricha et al. reported on the use of BoNT-A
in the gastrointestinal (GI) tract [8], demonstrating that BoNT-A could be safely injected into the smooth muscle
of the GI tract and that it decreased resting pressure of the lower esophageal sphincter (LES) in piglets. This
novel study opened up an entirely new field of research and therapy for many GI motility disorders.
Nowadays, BoNT serotype A is the most widely used clinically, as it can inhibit the muscular contractions of
smooth and striated muscles [9], and this property has been used in the treatment of some digestive illnesses
[10,11]. Gui et al. was the first to show that intramuscular injections of BoNT-A in the gastric wall of
laparatomized normal-weight rats significantly reduced their food intake and body weight [12]. In this
prospective trial, they measured daily food intake over 7 weeks and body weight over 10 weeks in three groups
of rats: a control group (no treatment; n = 5), a laparotomy group with antral BoNT-A injection (20 IU; n = 14),
and a laparotomy group with saline antral injection (n = 14). They found that BoNT-A injection led to a
significant reduction in both food intake (p < 0.05) and weight (p < 0.001) compared with the sham injection
group. Subsequently, similar findings were confirmed by Coskun et al. in obese rats [13]. In humans, injections
with BoNT-A has led to conflicting results, probably coming from differences in the sites of administration
(antrum and/or fundus region), the doses of the toxin, and patient selection [14]. Very recently, in a meta-analysis
and meta-regression of eight studies, Bang et al. analyzed a total of 115 patients (79 treated vs. 36 placebo). Wide
area injection including the fundus or body rather than the antrum only and multiple injections (>10) were
associated with weight loss [15].
De Moura et al. [16] assessed a systematic review to evaluate the meta-analysis performed by Bang et al. [15]
using a methodology based on the guidelines from the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) statement and the Assessment of Multiple Systematic Reviews (AMSTAR) [17,18].
They found that serious aspects compromise the reliability, consistency, and applicability of the
recommendations about the use of botulinum toxin A in the treatment of obesity, concluding that the meta-
analysis of Bang et al. [15] is the weakest form of evidence and has no power to support any recommendation
[19,20].
This review discusses the available mechanism and current medical evidence of intragastric BoNT-A injection
for treating obesity.
2. Botulinum Toxin
BoNT-A is a neurotoxic protein produced by Gram-positive, anaerobic bacterium Clostridium botulinum [21].
There are seven different serotypes of botulinum toxins designated by the letters A, B, C1, D, E, F, and G. Each
serotype has more subtypes (e.g., the subtype A contains four distinct subtypes). All serotypes have a similar
chemical structure and are neurotoxins, with the exception of the C2 subtype [22,23]. Recently, a new serotype
(BoNT/H) has been proposed but has yet to be validated [24].
Botulinum toxin acts in the neuromuscular junction (endplate) blocking the release and the effects of
acetylcholine, an acetic acid ester and choline, responsible for neurotransmission in the central nervous system
(CNS) and peripheral nervous system (PNS) [25].
Botulinum toxin is a metal-protein with endopeptidase activity. The metal in question is zinc. The general
structure presents two chains of a total weight of approximately 150 kDa. They are a heavy chain (H, 100 kDa)
and a light chain (L, 50 kDa) joined by a disulfide bridge. The heavy chain is in turn constituted from the N-
terminal domain (HN) and the C-terminal domain (HC). Each botulinum toxin is initially synthesized as a double
polypeptide, but the biological activity requires a post-translational proteolysis that cleaves the polypeptide in
two separate portions [26]. In nature, the botulinum toxin exists as complex consisting of a protective coating of
catalytically inactive proteins, called “proteins associated with neurotoxins” (NAPs, neurotoxin-associated
proteins). The NAPs are a set of five proteins: (i) four different hemagglutinins (HP, hemagglutinizing proteins)
and (ii) one non-hemagglutinin (NHP, Non-hemagglutinizing protein). The NAPs are synthesized by Clostridium
and defend the neurotoxin from possible destruction by the gastric activity of the stomach. However, the
presence of the NAPs involves the occurrence of severe and frequent immune responses and a greater difficulty
in obtaining a precise dosage of the toxin [27].
The two chains that constitute the molecular organization of BoNT-A have different functions. The heavy chain
binds to a specific receptor present on the cell membrane of the synaptic button, the synaptic vesicle glycoprotein
2 (SV2 receptor). This binding starts an invagination of the membrane, and a consequent endocytosis that makes
able the botulinum toxin to penetrate inside the synaptic button. The light chain is a protease and performs the
catalytic function of the toxin. The mechanism of action of BoNT-A is based on three key events: (i) binding to
receptors; (ii) internalization and translocation into the cytoplasm; and (iii) enzymatic modification of the target
[28].
2.1. Binding to Receptors
Neuromuscular cholinergic synapse is a structure used for the transduction of motor stimulation by the nervous
system and muscle apparatus of an organism. Its main function is to translate an electrical pulse, coming from the
neuronal axon, in the chemical stimulus by means of the release of the neurotransmitter acetylcholine.
When the action potential reaches the synaptic terminal, there is an influx of calcium (Ca ), due to the opening
of voltage-gated ion channels, from the extracellular environment. This ion, interacting with various synaptic
proteins, determines the fusion of vesicles containing the neurotransmitter, causing the release of the latter (Ach)
[29].
In the synaptic cleft, acetylcholine will bind to nicotinic cholinergic receptors of the postsynaptic region. These
receptors are ion channels that bind two molecules of Ach and undergo a conformational change determining
opening channels. At this point, there is an ionic influence, at the muscular level, which leads to the mobilization
of Ca  from intracellular stores with a consequent contraction of muscle fibers. In the body fluids, the
botulinum toxin is able to reach the muscle junctions that, following its internalization, will carry out the toxic
activity adapted to block the transmission of nerve impulses [30].
2.2. Internalization and Translocation into the Cytoplasm
Neurotransmitters are small molecules of a different nature that are released from neurons and are able to evoke a
response in a postsynaptic element. They are not dissolved in the cytoplasm but are accumulated in special
vesicles of synapses. After the action of the potential axon, the fusion of the vesicles occurs with a consequent
release of the molecules contained therein. This process is not spontaneous, nor left to chance. There is, in fact, a
fine tuning of all the processes that lead to neuroexocytosis: the mobilization of vesicles, fusion with the cell
membrane, and subsequent endocytosis for the recovery of the functionality [31].
The neurotransmitter is accumulated in the vesicles lumen through a specific carrier that uses the H  gradient
created by ATPase activity of a proton pump. Many of the vesicles at synaptic terminals are anchored to actin
cytoskeleton through interactions regulated by proteins such as synapsin. They should therefore be freed from
this constraint in order to reach the region that is “active” of synapses. After mobilization, the vesicles fuse with
the membrane through various processes. In the tethering process, the vesicles are able to approach and interact
with the presynaptic membrane in special zones called “active zones” [32]. The docking process allows the
vesicles to binds to the plasma membrane forming the SNARE complex (SNAPs-receptor). This complex
consists of three proteins: syntaxin (cell membrane), SNAP-25 (cell membrane), and VAMP/synaptobrevin
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(vesicle membrane) [33].
During the priming process, the vesicles mature and are able to fuse with the cell membrane perceiving only one
activating stimulus. At this point, the release of calcium induced by an action potential is able to melt the vesicle
membrane with the cell, thus permitting the outflow of neurotransmitters. After this step, the vesicles must be
endocitate to regain functionality. The SNARE complex serves as a receptor for the cytosolic factors a, b, and g
SNAPs (synaptosomal associated proteins), which, in turn, mediate the interaction with the NSF (N-
ethylmaleimide-sensitive fusion protein). At this point, the ATPase is able to dissociate the complex, and the
vesicles can be retrieved via endocytosis. The endocytosis is characterized by the formation of a coating of
clathrin and by the action of a dynamin, GTP-dependent protein, closing the fusion of the neck vesicles [34].
2.3. Enzymatic Modification of the Target
SNARE is a trimeric complex composed of the proteins: VAMP/synaptobrevin, SNAP-25, and syntaxin.
Depending on their location, these proteins are classified as v-SNARE (vescicle) if associated with the vescicular
membrane, or t-SNARE (target) when associated with the cytoplasmic. VAMP (vescicle associated membrane
protein) is a protein of 13 or 23 kDa (VAMP-1 and VAMP-2 are neuronal isoforms). VAMP is anchored to the
vescicular membrane by the carboxyl terminal, while the amine terminal is completely in the cytosol. VAMP is
also involved in processes of exocytosis of non-neuronal cells [35,36].
SNAP-25 (synaptosomal associated protein of 25 kDa) contains 206 amino acids. The peculiarity of this protein
resides in the absence of intramembrane segments. Its anchoring is due to the palmitoylation of four cysteines
located in the center of the protein chain. There are several isoforms of SNAP-25, for example, SNAP-29 and
SNAP-23; all are involved in the regulation of exocytosis phenomena [37].
Syntaxin is a plasma membrane protein of about 35 kDa that presents a transmembrane segment (projecting the
synaptic space) near the carboxyl terminus. This protein, in addition to binding to VAMP and SNAP-25, also
interacts with Synaptotagmin, a calcium-sensitive protein, involved in the vesicular membrane fusion and,
therefore, in the release of neurotransmitter (SNAP-25 is also able to interact with Synaptotagmin) [38].
Crystallography studies have enabled an understanding of how various proteins interact with each other for the
formation of the SNARE complex. It is composed of four parallel helices (two of which belong to SNAP-25)
tightly wound on themselves to form a very stable complex. The proteins of the SNARE complex are targets of
botulinum toxins. The cutting of these proteins may result in a failure pairing of the same or not very stable
interaction that will give rise to a SNARE complex non-functional or however scarcely efficient. It was shown
that the BoNT-As are not able to perform their proteolytic action on complexed protein, but only when they are
in free form [39].
BoNT-A acts on a pre-synaptic level, blocking the release of the neurotransmitter acetylcholine at the
neuromuscular junction. Acetylcholine is the neurohormone that allows the SNC to communicate with the
muscle cells stimulating the striated determining muscle contraction, and allows the SNA to communicate with
the sweat glands stimulating their secretion. The different serotypes of botulinum toxin have specific molecular
targets: the toxin A catalyzes the cleavage of SNAP-25 molecules, the toxin B catalyzes the cleavage of VAMP,
the serotypes D, F, and G also have VAMP as a substrate, and the serotypes C1 and E have SNAP-25 as a
substrate [40].
The cleavage of these proteins destroys the formation of functional SNARE complexes, preventing the adhesion
and the fusion of the vesicles with the presynaptic membrane and inhibiting the exocytosis of acetylcholine. In
this way, the signal conduction of cholinergic neurons is interrupted. The various serotypes have the ability to
specifically hydrolyze a single peptide bond of these proteins, and there is a kind of structural recognition of
targets by the botulinum toxins. BoNT-A also acts on other nerve endings. In fact, it was observed, in preclinical
studies, that BoNT-A reduces pain by inhibiting the neurotransmission of substance P, glutamate, and calcitonin
gene-related peptide. The proteins of the SNARE complex play a key role in the release of acetylcholine,
promoting the fusion of the synaptic vesicle membrane in which the acetylcholine is stored with the synaptic
membrane button [41].
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SNAP-25 is hydrolyzed, and this event makes the fusion between the membrane of synaptic vesicles and the
synaptic button impossible. In this way, the acetylcholine can not be released in the synaptic cleft determining the
characteristic flaccid paralysis of the treated muscles. Later, in a few days, the sprouts appear (nerve
germination); at 28 days, they will have freed the acetylcholine. This production is, however, insufficient for a
regular decrease. In 2–3 months, it can enjoy a muscle recovery for the release of an effective concentration of
acetylcholine. Meanwhile, the production of SNAP-25 continues. In 3–6 months, the plaque resumes its normal
function, while the sprouts disappear [41].
3. Mechanisms of BoNT-A in the GIT Muscle
There have been several studies showing that BoNT-A inhibits the vesicular neurotransmitter release from
neurons and is widely used as a therapeutic agent for a variety of spastic muscular disorders including those
involving visceral muscle [42,43]. BoNT-A acts to inhibit acetylcholine release at the neuromuscular junction,
hypothetically delaying gastric emptying and inhibiting ghrelin secretion, a potent hormone released from the
gastric fundus that stimulates hunger [44]. Although BoNT-A can clearly inhibit the release of acetylcholine,
little else is known about its effects in the GIT (Gastrointestinal) muscle. In gastrointestinal smooth muscle,
botulinum toxin appears to also reduce cholinergic transmission by inhibiting Ach release, as shown in in vitro
[8] and in vivo studies [45,46]. SNAP-25, the substrate for botulinum toxin, is also present in gastrointestinal
smooth muscle, suggesting an additional site for botulinum toxin [47].
James et al. [48] demontrated that BoNT-A has a dual effect on gut smooth muscle tone, with low concentrations
(2 IU/mL) inhibiting neurally mediated contractile responses and higher concentrations (10 IU/mL), directly
inhibiting smooth muscle contractility in response to exogenous Ach. Enteric motor neurons can be considered
either excitatory or inhibitory on smooth muscle tone; thus, excitatory motor neurons contain both Ach and the
tachykinin substance P (SP) [49,50]. Blocking both Ach and SP release from enteric neurons, BoNT-A induces
paralysis of gastrointestinal smooth muscle not only because of a lack of Ach but also from the lack of
endogenous SP that is required to maintain sensitivity to exogenous contractile agonists. This study demonstrated
a novel role for coneurotransmission in the enteric nervous system with important physiological and clinical
implications [51]. SP depolarizes the membrane potential inducing contraction in gastrointestinal smooth muscle.
It is an undecapeptide belonging to the tachykinin family and can induce strong contractions in pylorus via
neurokinin 1 receptor (NK1R), the preferred receptor for SP [52,53]. Experimental evidence suggests that BoNT-
A directly inhibits SP-induced pyloric smooth muscle contractility in a concentration- and time-dependent
manner [54].
The effects of BoNT-A are time and concentration dependent as axonal sprouting and accumulation of
extrajunctional Ach lead to slow reversal of denervation [55]. BoNT-A has been found to be effective in the
treatment of spastic disorders of smooth muscle in the upper and lower gastrointestinal tract. Case reports and
prospective trials have shown positive results with BoNT-A administration in the treatment of diffuse esophageal
spasm, achalasia, oropharyngeal dysphagia, anismus, anal fissures, and anterior rectocele [56,57,58,59,60,61].
4. Clinical Studies of Intragatsric BoNT-A for Obesity
Several studies have supported the clinical use of the BoNT-A injection into the gastric antrum in obese patients.
Rollnik et al. demonstrated the results of BoNT-A gastric antrum injection in treating obesity, and they showed a
reduction in body weight of 9 kg and 32.5% of the caloric daily intake four months after treatment [62].
García-Compean et al. performed, by endoscopy, prepyloric antral gastric wall injection with 100 UI of BoNT-A
in 12 obese patients, and they evaluated body weight and solid gastric emptying before, and 4 and 12 weeks after,
treatment. The results demonstrated that body weight and gastric emptying did not show significant changes
compared with baseline values. Abnormal gastric emptying (solid gastric retention at 90 min > 50%) was
observed in 22% of patients after 4 weeks and in 25% after 12 weeks [63]. In another pilot study, Albani et al.
[64] analyzed the efficacy of 500 UI endoscopic BoNT-A injections to the gastric antral region in eight patients
with severe obesity and multiple dietary treatment failures. They observed no clinically significant side effects
and a reduction in body weight at one month, independently of a specific diet. At four months, three of the
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patients demonstrated further weight loss.
Junior et al. reported their experience of different doses (200–300 IU) of antropyloric region BoNT-A injection,
at different sites, in 12 patients with class III obesity, and body weight and gastric emptying time did not reduce
significantly before and after injection over a period of 12 weeks. All patients reported a feeling of early satiety
[65]. In a randomized double blind controlled trial, with 14 obese patients assigned to three groups in which Btx-
A at 133 IU, Btx-A at 200 IU, and saline at 8 mL was injected into the gastric angulus in eight sites around the
gastric antral circumference, all male patients (8 patients), both in the BTX133 and BTX200 groups, reported
weight loss, which was not statistically significant. In the saline group, only one male patient lost weight. The
effects on gastric emptying were variable. Most of the BoNT-A-treated patients reported a reduced appetite [66].
A double blind controlled study evaluated the responses of 24 morbidly obese patients at 200 IU BoNT-A or a
placebo into the antrum and fundus of the stomach by intraparietal endoscopic administration. All patients treated
with BoNT-A had significantly greater amounts of weight loss after 8 weeks. In addition, this study found a
prolonged gastric emptying time and reduced maximal gastric capacity for liquids [67]. Similar results have been
found in an open label study of 10 obese adults who received 100 units (4 patients) or 300 units (6 patients) of
BoNT-A and were followed for 16 weeks [68].
A randomized controlled trial by Li et al. [69] in 20 obese patients demonstrated statistically significant weight
loss, ranging from 1 to 12 kg and decreased triglyceride levels in those injected with BoNT-A. Gastric emptying
times were longer, and a decrease in fasting ghrelin levels was appreciated. However, a larger randomized
placebo controlled trial by Topazian et al. [70], who enrolled 60 obese patients in a six-month trial, demonstrated
a delay in gastric emptying without the effects of early satiety, in altered eating behaviors, or in weight loss. In
this study, only antral injections were performed as opposed to both antral and fundal injections. These results
may reflect the relatively short duration of action of BoNT-A and certainly indicate the need for further
evaluation of this technique as a method for weight loss. In summary, differences among several open-label
studies and double-blind, placebo-controlled trials have been reported (Table 1).
Table 1
Botulinum toxin (BoNT/A) for the treatment of obesity.
5. Conclusions
In summary, given the minimal adverse events noted in studies and the widespread availability, BoNT-A has the
potential to have a large role in the treatment of obesity. However, additional investigation into the sites of
BoNT-A injection and the optimum dosage are necessary. One major limitation with BoNT-A is its relatively
short duration of action, which is approximately three to six months. Furthermore, data regarding long-term
outcomes is lacking and additional studies may be warranted. The mechanisms of BoNT-A treatments include
centrally mediated alterations of appetite or satiation, and the alteration of stomach capacity, gastric emptying, or
incretin hormones. BoN-TA inhibits acetylcholine release at the neuromuscular junction, hypothetically delaying
satiation, and appetite. Neurotransmission in the gastrointestinal (GI) tract relies on several mediators.
Acetylcholine represents the most important stimulating mediator both of the intrinsic (myoenteric) and extrinsic
(vagal) nervous systems [71]. Botulinum toxin A binds with high affinity to cholinergic nerve endings and
selectively inhibits their activity [72]. Cholinergic neurons are localized in different brain regions, and activation
of their receptors has important roles in the regulation of various appetitive behaviors, in part through their
interactions with mesolimbic dopamine (DA) systems. The existence of a cholinergic interneurons activity in the
nucleus accumbens (NAc) and cholinergic projections to the ventral tegmental area (VTA), which function to
affect feeding behavior, have been demonstrated. These output pathways may have distinct roles in promoting
either satiety or appetite, depending on their specific co-transmitters [73]. DA promotes the appetite or satiety
through activation through activation of a select GABA output pathway and cholinergic activation of these
pathways via muscarinic receptors. Behavioral studies support the theory that increasing levels of accumbens
ACh can promote satiety. In a very recent study, it has been demonstrated that increased extracellular ACh in the
NAc can inhibit feeding. Thus, by promoting ACh levels in the synapse, food intake is attenuated [74].
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Future treatment may be individualized based on quantitative GI and behavioral traits measured in obese patients.
Additional studies are needed to assess the role of botulium toxin in the treatment of obesity.
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